Pfizer Phase 3 TALAPRO-3 trial links TALZENNA plus XTANDI to improved rPFS in HRR-mutated mCSPC

Pfizer Inc.

Pfizer Inc.

PFE

0.00
  • Pfizer reported positive topline results from the Phase 3 TALAPRO-3 trial evaluating TALZENNA (talazoparib) plus XTANDI (enzalutamide) in homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer.
  • The study met its primary endpoint, showing improved investigator-assessed radiographic progression-free survival versus placebo plus XTANDI.
  • Consistent radiographic progression-free survival benefit was reported in patients with BRCA and non-BRCA HRR gene alterations.
  • An interim analysis showed a trend toward improved overall survival, a key secondary endpoint.
  • Pfizer said the results will be submitted for presentation at an upcoming medical congress and discussed with global health authorities for potential regulatory submissions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603190645BIZWIRE_USPR_____20260318_BW849596) on March 19, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.